Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has become the standard care for patients with non–small cell lung cancer (NSCLC) positive for activating mutations of EGFR [1-7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.